1. In Vitro and In Vivo Antibacterial Activity of Gliotoxin Alone and in Combination with Antibiotics against Staphylococcus aureus
- Author
-
Sonia Algarate, Eva M. Galvez, Laura Comas, Concepción López, Sergio Redrado, M. Isabel Millán-Lou, Cristina Seral, Antonio Rezusta, Patricia Perez Esteban, Maykel Arias, Julián Pardo, M. Pilar Domingo, European Commission, Gobierno de Aragón, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Aspanoa, Gilead Sciences, Asociación Carrera de la Mujer Ciudad de Monzón, ARAID Foundation, Esteban, Patricia [0000-0003-4123-3524], Redrado, Sergio [0000-0002-8404-0012], Comas, Laura [0000-0002-3843-1231], Domingo, María Pilar [0000-0002-6829-8769], Algarate, Sonia [0000-0002-0036-663], Rezusta, Antonio [0000-0001-7294-245X], Pardo, Julián [0000-0003-0154-0730], Arias, Maykel [0000-0002-9730-2210], Gálvez Buerba, Eva Mª [0000-0001-6928-5516], Esteban, Patricia, Redrado, Sergio, Comas, Laura, Domingo, María Pilar, Algarate, Sonia, Rezusta, Antonio, Pardo, Julián, Arias, Maykel, and Gálvez Buerba, Eva Mª
- Subjects
Staphylococcus aureus ,gliotoxin ,medicine.drug_class ,Health, Toxicology and Mutagenesis ,Resistance ,vancomycin ,Antibiotics ,lcsh:Medicine ,MRSA ,Toxicology ,medicine.disease_cause ,Microbiology ,Aspergillus fumigatus ,03 medical and health sciences ,chemistry.chemical_compound ,Gliotoxin ,Vancomycin ,In vivo ,antibiotic ,synergism ,medicine ,030304 developmental biology ,0303 health sciences ,Aspergillus ,biology ,030306 microbiology ,lcsh:R ,Synergism ,biology.organism_classification ,Antimicrobial ,VISA ,chemistry ,medicine.drug - Abstract
7 figures, 2 tables., Multidrug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) is one of the major causes of hospital-acquired and community infections and pose a challenge to the human health care system. Therefore, it is important to find new drugs that show activity against these bacteria, both in monotherapy and in combination with other antimicrobial drugs. Gliotoxin (GT) is a mycotoxin produced by Aspergillus fumigatus and other fungi of the Aspergillus genus. Some evidence suggests that GT shows antimicrobial activity against S. aureus in vitro, albeit its efficacy against multidrug-resistant strains such as MRSA or vancomycin-intermediate S. aureus (VISA) strainsis not known. This work aimed to evaluate the antibiotic efficacy of GT as monotherapy or in combination with other therapeutics against MRSA in vitro and in vivo using a Caenorhabditis elegans infection model., This research was funded by FEDER (Fondo Europeo de Desarrollo Regional, Gobierno de Aragón (Group B29_17R), Ministerio de Ciencia, Innovación e Universidades (MCNU), Agencia Estatal de Investigación (SAF2017-83120-C2-1-R), ASPANOA, GILEAD (GLD18/00100), Donación Javier Saura Carceller, and Carrera de la Mujer de Monzón. J.P. was supported by Fundacion Aragon I+D (ARAID). P.E. was supported by Fondo Garantıa Empleo Juvenil/INAEM. L.C. and S.R. were granted funding by a DGA predoctoral contract. M.A. was granted funding by a Juan de la Cierva contract of Spanish Ministry of Economy and Competitiveness (FJCI-2017-31629).
- Published
- 2021